Encapsulation of Leflunomide (LFD) in a novel niosomal formulation facilitated its delivery to THP-1 monocytic cells and enhanced Aryl hydrocarbon receptor (AhR) nuclear translocation and activation | Zendy

Mahsa Hasani | Zendy; Neda Abbaspour Sani | Zendy; Behnaz Khodabakhshi | Zendy; Mehdi Sheikh Arabi | Zendy; Saeed Mohammadi | Zendy; Yaghoub Yazdani | Zendy

Open Access

Encapsulation of Leflunomide (LFD) in a novel niosomal formulation facilitated its delivery to THP-1 monocytic cells and enhanced Aryl hydrocarbon receptor (AhR) nuclear translocation and activation

Author(s) -

Mahsa Hasani,

Neda Abbaspour Sani,

Behnaz Khodabakhshi,

Mehdi Sheikh Arabi,

Saeed Mohammadi,

Yaghoub Yazdani

Publication year - 2019

Publication title -

daru journal of pharmaceutical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.645

H-Index - 42

eISSN - 2008-2231

pISSN - 1560-8115

DOI - 10.1007/s40199-019-00293-0

Subject(s) - aryl hydrocarbon receptor , thp1 cell line , chemistry , encapsulation (networking) , leflunomide , pharmacology , medicine , biochemistry , cell culture , biology , transcription factor , computer science , gene , computer network , genetics , methotrexate

Leflunomide (LFD) is an Aryl hydrocarbon receptor (AhR) agonist and immunomodulatory drug with several side effects. Niosomes are novel drug delivery systems used to reduce the unfavorable effects of drugs by enhancing their bioavailability, controlling their release and targeting specific sites.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research